Genflow Biosciences PLC: A European pioneer in the field of longevity

Genflow Biosciences PLC is a UK-based biotechnology company developing gene therapies designed to target the ageing process and to reduce and delay the incidence of age-related diseases.

This will be done through novel therapeutics targeting aging in humans by using adeno associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells.

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has made headway across its gene therapy pipeline, reporting strong mid-year momentum in its programmes targeting age-related diseases, muscle loss, and degenerative eye conditions.

The update also highlighted important developments in intellectual property and new strategic collaborations.

The London-listed biotech, which specialises in therapies based on a centenarian variant of the SIRT6 gene, has struck new partnerships with Belgian research centre CER Groupe and medical artificial intelligence firm Heureka Labs, a spin-out from Duke University.

These moves are expected to strengthen Genflow’s research and development infrastructure as it prepares for upcoming clinical trial applications.

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has signed a long-term agreement with its Belgian research partner CER Groupe to support the development of its gene therapy programmes aimed at tackling ageing.

The Master Service Agreement sets out a framework for how the two companies will work together, expanding on a partnership that has already been running informally for several years.

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has taken a step forward in its bid to protect a key gene therapy technology in Japan, as the country’s patent office moved a core application into the national examination stage.

The patent, covering variants of a gene known as SIRT6, which is linked to age-related diseases, was originally filed in May 2022.

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s strong progress in 2024 and its priorities for 2025. Leire outlined four major projects: the MASH project targeting liver disease, advancements in sarcopenia, research on Werner syndrome through synthetic organ development, and the innovative life-extension project for dogs.

The MASH project is in its preclinical phase, focusing on demonstrating efficacy and ensuring compliance with manufacturing standards to progress toward clinical trials. Sarcopenia research, addressing age-related muscle loss, aims to restore mitochondrial function, potentially benefiting the immune system and brain health. Werner syndrome research leverages synthetic liver models, enabling more accurate preclinical results for clinical trials.

Additionally, the company is conducting groundbreaking trials on life-extension solutions for dogs. Using a cohort of ageing dogs, Genflow aims to determine the efficacy of its treatment by late 2025 or early 2026. Leire expressed enthusiasm about these projects and the potential they hold for both humans and animals.